Source comparison
Best CJC-1295 Dosage Growth Hormone Release: Evidence-Based Comparison
Standalone DAC 1–2 mg Once weekly 30–60 ng/mL Simple administration; sustained baseline elevation; less dramatic pulsatile peaks Standalone No DAC 200 mcg 2–3x daily 2.8–4.2 mg 40–70 ng/mL Preserves pulsatile pattern; higher peptide consumption; multiple daily
This comparison does not assign a generated winner or score.
- Standalone DAC
- 1–2 mg
- Once weekly
- 30–60 ng/mL
- Simple administration; sustained baseline elevation; less dramatic pulsatile peaks
- Standalone No DAC
- 200 mcg
- 2–3x daily
- 2.8–4.2 mg
- 40–70 ng/mL
- Preserves pulsatile pattern; higher peptide consumption; multiple daily injections
- No DAC + Ipamorelin (100:100 mcg)
- 100 mcg CJC / 100 mcg Ipa
- 2x daily
- 1.4 mg CJC total
- 60–90 ng/mL
- Synergistic amplification; lower individual doses; most cost-effective per unit IGF-1 gain
- No DAC + GHRP-2 (100:200 mcg)
- 100 mcg CJC / 200 mcg GHRP-2
- 70–100 ng/mL
- Highest peak GH levels; increased appetite from GHRP-2; cortisol/prolactin elevation possible
- DAC + Hexarelin (1 mg:100 mcg)
- 1 mg CJC weekly / 100 mcg Hex 2x daily
- Mixed schedule
- 1 mg CJC total
- 50–80 ng/mL
- Combines sustained DAC with pulsatile GHRP; desensitisation risk with chronic hexarelin use
- The comparison table shows dosing structures and expected IGF-1 response ranges based on research-protocol observations. Individual response varies—factors like age, baseline GH status, body composition, sleep quality, and training volume all influence the magnitude of IGF-1 elevation. The 'best' protocol depends on whether you prioritise simplicity (DAC standalone), physiological pulsatility (No DAC standalone), or peak GH output (combination with GHRP).